IMV to Provide Updated Clinical Data at 2019 ASCO Annual Meeting on Lead Candidate DPX-Survivac in Ovarian Cancer & Other Sol...
April 18 2019 - 7:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology corporation, today announced that two of its
abstracts have been accepted for presentation at the upcoming 2019
American Society of Clinical Oncology (ASCO) Annual Meeting, which
takes place May 31 – June 4 in Chicago, IL.
“Despite advances in other cancer treatment regimens, ovarian
cancer remains a particularly difficult-to-treat disease, and one
that represents one of the most underserved areas of the treatment
landscape,” said Frederic Ors, Chief Executive Officer
at IMV. “Our presentations at ASCO will allow us to update
this important scientific audience on the potential of DPX-Survivac
monotherapy and on the progress we have made since our
groundbreaking ASCO 2018 presentation.”
Presentation details are as follows:
Poster Title: “DPX-Survivac and intermittent low-dose
cyclophosphamide (CPA) with or without epacadostat (E) in the
treatment of subjects with advanced recurrent epithelial ovarian
cancer (DeCidE1 trial): T cell responses and tumor infiltration
correlate with tumor regression.”Abstract Number:
5576Session Title: Gynecologic CancerDate and Time:
June 1, 2019, 1:15 – 4:15 p.m. CT
Poster Title: “Early response assessment through
multiparametric MRI based endpoints in a phase II multicenter study
evaluating the efficacy of DPX-Survivac, intermittent low dose
cyclophosphamide (CPA) and pembrolizumab combination study in
subjects with solid tumors.”Abstract Number:
e14245Session Title: online publication only on May 15,
2019, 5:00 p.m. ET
ASCO will publish the official abstracts on its meeting website
in advance of the ASCO Annual Meeting at 5:00 p.m. ET on May 15.
The cut-off date for inclusion of data in the abstract was February
12, 2019. The final conference presentation will include additional
data collected between the abstract submission cutoff and the
presentation itself.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory
approval of DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190418005217/en/
MediaAndrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
Investor RelationsMarc Jasmin, IMV Senior
Director, Investor Relations and CommunicationsO: (902) 492-1819
ext: 1042M: (514) 917-9481 E: mjasmin@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024